Skip to content
Screener

Kymera Therapeutics KYMR Q2 2026 earnings

Reported August 5, 2026 · Before market open

Revenue$65.0MBeat by $32.2M
EPS-$0.62Beat by $0.09
Revenue estimate$32.8M
EPS estimate-$0.71
“Kymera is delivering in a pivotal period of execution, with multiple clinical-stage programs advancing, important data catalysts ahead, and growing conviction in the potential of oral degrader medicines to transform the standard of care for chronic, debilitating immunological diseases. The rapid completion of enrollment in our KT-621 BROADEN2 Phase 2b trial in atopic dermatitis nearly six months ahead of our original timeline is a powerful example of the immense interest from clinicians and patients in a once-daily oral therapy and excellent execution from the Kymera team. The accelerated timeline enables us to pull forward our expected topline readout to year-end 2026, positions us for an earlier than anticipated start to Phase 3 trials next year, and ultimately allows us to move faster for patients who are waiting for new options.”
Nello Mainolfi

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$3.3M
EPS estimate-$1.25

Financials

Q2 2026

Income statement

See full
Revenue$65.0M+466%
Operating income-$75.6M+10.6%
Net income-$61.2M+20.1%
EPS (diluted)-$0.62+34.7%

Balance sheet

See full
Cash & equivalents$124.5M-62.9%
Total debt$80.1M-8.5%
Total equity$1.5B+55.4%
Total assets$1.6B+45.5%

Cash flow

See full
Operating cash flow-$54.1M+9.7%
CapEx$473.0K-31.9%
Free cash flow-$54.5M+10.0%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$9.67B+181%
Enterprise value$9.63B+202%
P/S92.1×+15.2×

Profitability

See full
Operating margin-333.5%-114pp
Net margin-285.3%-99.7pp
FCF margin-226.6%-84.9pp

Returns & leverage

See full
Return on equity-24.2%-5.2pp
Debt / equity0.1×0.0×
Current ratio10.3×+2.0×

FAQ

When did Kymera Therapeutics report Q2 2026 earnings?
Kymera Therapeutics (KYMR) reported Q2 2026 earnings on August 5, 2026 before market open.
What were Kymera Therapeutics's Q2 2026 revenue and EPS?
Kymera Therapeutics reported revenue of $65.0M and eps of $-0.62 for Q2 2026.
Did Kymera Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $32.8M by $32.2M. EPS beat the consensus estimate of $-0.71 by $0.09.
How did Kymera Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 466.4% from $11.5M a year earlier and eps grew 34.7% from $-0.95.
Where can I find Kymera Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-333834) and the 10-Q periodic report (0001193125-26-333849) directly on SEC EDGAR. The filing index links above go to sec.gov.